HRT Financial’s Jasper Therapeutics JSPR Stock Holding History

HRT Financial’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,797	Closed	-$82K	–	3277
2025 Q2	$82K	Buy	+14,797	New	+$72.9K	﹤0.01%	2235
2024 Q2	–	Sell	-23,271	Closed	-$683K	–	2657
2024 Q1	$683K	Buy	+23,271	New	+$413K	﹤0.01%	1085
2023 Q3	–	Sell	-4,126	Closed	-$56K	–	2753
2023 Q2	$56K	Buy	+4,126	New	+$61.3K	﹤0.01%	2018
2021 Q3	–	Sell	-3,449	Closed	-$343K	–	3516
2021 Q2	$343K	Hold	3,449	–	–	﹤0.01%	2063
2021 Q1	$342K	Sell	3,449 -10	-0.3%	-$1.02K	﹤0.01%	2030
2020 Q4	$346K	Buy	3,459 +10	+0.3%	+$995	0.01%	1206
2020 Q3	$342K	Buy	+3,449	New	+$345K	0.01%	1067

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

HRT Financial's JSPR Position: Q3 2025 in Review

HRT Financial sold out of Jasper Therapeutics (JSPR) in Q3 2025, closing a stake of 14,797 shares — an estimated $82K sold.

HRT Financial first reported a position in JSPR in Q3 2020 and held it in 7 quarters. The position peaked at $683K in Q1 2024. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

HRT Financial reported no remaining Jasper Therapeutics position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 14,797 Jasper Therapeutics shares in Q3 2025, an estimated $82K.
HRT Financial first reported a position in Jasper Therapeutics in Q3 2020 and held it in 7 quarters.
HRT Financial's Jasper Therapeutics position peaked at $683K in Q1 2024.
60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.